Parkside Financial Bank & Trust Has $278,000 Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Parkside Financial Bank & Trust boosted its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 7.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,007 shares of the biopharmaceutical company’s stock after purchasing an additional 217 shares during the period. Parkside Financial Bank & Trust’s holdings in Gilead Sciences were worth $278,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of GILD. FMR LLC increased its holdings in Gilead Sciences by 79.4% in the third quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company’s stock valued at $2,780,329,000 after purchasing an additional 14,680,161 shares during the period. Wellington Management Group LLP increased its holdings in Gilead Sciences by 50.9% in the third quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company’s stock valued at $2,900,921,000 after purchasing an additional 11,665,593 shares during the period. Pacer Advisors Inc. increased its holdings in Gilead Sciences by 723.3% in the fourth quarter. Pacer Advisors Inc. now owns 6,434,665 shares of the biopharmaceutical company’s stock valued at $594,370,000 after purchasing an additional 5,653,075 shares during the period. Point72 Asset Management L.P. increased its holdings in Gilead Sciences by 350.1% in the third quarter. Point72 Asset Management L.P. now owns 2,305,270 shares of the biopharmaceutical company’s stock valued at $193,274,000 after purchasing an additional 1,793,145 shares during the period. Finally, Jennison Associates LLC acquired a new stake in Gilead Sciences in the fourth quarter valued at $87,163,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $114.31 on Friday. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $114.77. The stock’s 50 day moving average price is $97.42 and its 200-day moving average price is $90.05. The company has a market capitalization of $142.46 billion, a PE ratio of 308.95, a PEG ratio of 0.71 and a beta of 0.18. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. On average, equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be paid a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.76%. The ex-dividend date of this dividend is Friday, March 14th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s payout ratio is presently 854.05%.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on GILD shares. Royal Bank of Canada increased their price objective on Gilead Sciences from $84.00 to $90.00 and gave the company a “sector perform” rating in a report on Wednesday, February 12th. DZ Bank upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 price target for the company in a report on Thursday, February 13th. Bank of America reiterated a “buy” rating and set a $109.00 price target on shares of Gilead Sciences in a report on Tuesday, December 10th. Wolfe Research started coverage on Gilead Sciences in a report on Friday, November 15th. They set an “outperform” rating and a $110.00 price target for the company. Finally, The Goldman Sachs Group increased their price target on Gilead Sciences from $85.00 to $96.00 and gave the stock a “neutral” rating in a report on Wednesday, February 12th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $102.08.

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the transaction, the chief financial officer now owns 129,873 shares in the company, valued at $11,863,898.55. The trade was a 1.89 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold 293,356 shares of company stock worth $29,166,240 in the last 90 days. Insiders own 0.16% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.